CXCL12 and breast cancer: Previous studies show that metformin downregulates the CXCL12/CXCR4 signaling in breast cancer and prostate cancer cell lines (45, 46); nevertheless, no data were supporting this pleiotropic effect of metformin in the small intestine so far.